Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.84 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21360549 | 0.92 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1MGLLHDAC4CA12 | |
| SCHEMBL24185218 | 0.91 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1MGLLHDAC4ATR | |
| SCHEMBL22165523 | 0.91 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1MGLLHDAC4ATR | |
| SCHEMBL2887251 | 0.91 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1MGLLHDAC4ATR | |
| SCHEMBL18874230 | 0.89 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1MGLLHDAC4CA12 | |
| SCHEMBL25498559 | 0.86 | L3MBTL3 (0.87) | L3MBTL3L3MBTL1HDAC4MEN1KMT2A | |
| SCHEMBL10195702 | 0.86 | L3MBTL3 (0.87) | L3MBTL3L3MBTL1MGLLHDAC4MEN1 | |
| SCHEMBL19226391 | 0.85 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1MGLLHDAC4MEN1 | |
| SCHEMBL26773746 | 0.84 | L3MBTL3 (0.84) | L3MBTL3L3MBTL1MGLLHDAC4CA12 | |
| SCHEMBL17271879 | 0.84 | L3MBTL3 (0.84) | L3MBTL3L3MBTL1MGLLHDAC4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823099-A | Preparation method of gedali plug | 浙江大学衢州研究院 | 2025-04-15 | — | — | CN | claimed |
| EP-4711369-A1 | 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| CN-119823099-A | Preparation method of gedali plug | 浙江大学衢州研究院 | 2025-04-15 | — | — | CN | disclosed |
| WO-2024245406-A1 | 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2024-12-05 | — | — | WO | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| WO-2021236650-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-6858641-B2 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-22 | — | — | US | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | L3MBTL3 3389/4885L3MBTL1 3278/4885MGLL 3259/4885 |
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | L3MBTL3 4863/4885L3MBTL1 4747/4885MGLL 4212/4885 |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | MTOR, RPTOR, RICTOR | L3MBTL3 3987/4885L3MBTL1 4179/4885MGLL 3135/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | L3MBTL3 4584/4885L3MBTL1 4029/4885MGLL 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.